

SELL TP: Rs 490 | ❤ 22% **r**

ECLERX SERVICES

IT Services

Good show but repeat act unlikely – downgrade to SELL

A mix of favourable yet transient dynamics saw eClerx (ECLX) staging a surprising operational beat in Q3FY20 (revenue up 3% QoQ, EBIT margin up 590bps). We do not expect a repeat performance anytime soon as management has not only guided for a soft Q4 due to offshore weakness and new project delays, but also reiterated a weak and volatile growth outlook. We raise FY21/FY22 EPS by 4%/3% and roll to a Mar'21 TP of Rs 490 (Rs 450 earlier). Growth visibility remains poor – cut to SELL from REDUCE.

Surprisingly good quarter...: ECLX reported a beat on both revenue and operating margins in Q3. Revenue at US\$ 51.8mn increased 3.4% QoQ alongside 22.8% EBIT margins (+590bps QoQ). EBIT at Rs 856mn (+42% QoQ, +56% YoY) was 47% ahead of our estimate.

...led by favourable but transitory factors: A convergence of unexpected revenue flows and other one-offs helped the company stage a surprise in Q3 – these included (1) project delays and thus below-expected calendar year-end roll-offs (likely adverse spillover effect in Q4), (2) milestone revenue accrual in fixed price engagements, (3) short-term project revenue in CLX business, and (4) upward rate revisions for full time employees (FTE) at select large clients.

Repeat show unlikely in near term: Management has guided for a soft Q4FY20 due to continued pressure in the offshore business and delays in new project ramp-up. ECLX further indicated a weak and volatile outlook, with muted commentary on business prospects from the top 10 clients.

Cut to SELL: Changing business dynamics over the last three years have structurally impaired the company's profit and growth profile. Even though margins appear to be bottoming out, growth visibility looks cloudy. SELL.

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue (Rs mn)	13,651	14,305	14,481	15,934	17,997
EBITDA (Rs mn)	3,668	3,092	3,365	3,665	4,129
Adj. net profit (Rs mn)	2,887	2,283	2,080	2,337	2,573
Adj. EPS (Rs)	74.5	60.1	55.3	62.1	68.3
Adj. EPS growth (%)	(15.7)	(19.4)	(8.0)	12.3	10.1
Adj. ROAE (%)	23.9	20.2	19.0	19.8	20.1
Adj. P/E (x)	8.4	10.4	11.3	10.1	9.2
EV/EBITDA (x)	5.5	6.3	6.0	5.6	4.8

Source: Company, BOBCAPS Research

BOB Capital Markets Ltd is a wholly owned subsidiary of Bank of Baroda

Important disclosures, including any required research certifications, are provided at the end of this report.

31 January 2020

Ruchi Burde research@bobcaps.in

Ticker/Price	ECLX IN/Rs 626
Market cap	US\$ 329.8mn
Shares o/s	38mn
3M ADV	US\$ 1.1mn
52wk high/low	Rs 1,175/Rs 388
Promoter/FPI/DII	50%/25%/25%
Source: NSE	

STOCK PERFORMANCE



Source: NSE





FIG 1 – DEC'19 QUARTER PERFORMANCE

(Rs mn)	Q3FY20	Q3FY19	Y₀Y (%)	Q2FY20	Q₀Q (%)	9MFY20	9MFY19	Y₀Y (%)
Revenues (US\$ mn)	51.8	50.2	3.2	50.1	3.4	152.8	149.6	2.1
Revenue	3,755	3,576	5.0	3,565	5.3	10,866.7	10,654.0	2.0
Operating Expenditure	2,723	2,905	(6.3)	2,785	(2.2)	8,394.3	8,369.0	0.3
Cost of revenues	1,891	1,830	3.3	1,910	(1.0)	5,724	5,282	8.4
as % of sales	50.4	51.2	-	53.6	-	52.7	49.6	-
SG&A expenses	832	1,075	(22.6)	875	(4.9)	2,670	3,087	(13.5)
as % of sales	22.2	30.1	-	24.5	-	24.6	29.0	-
EBITDA	1,032	671	53.8	780	32.3	2,472	2,285	8.2
Depreciation	176	123	42.9	177	(0.6)	525	319	64.3
EBIT	856	548	56.2	603	42.0	1,948	1,966	(0.9)
Other Income	115	(4)	_	87	-	284	373	_
PBT	970	544	78.5	690	40.7	2,232	2,339	(4.6)
Total Tax	222	154	43.9	206	7.8	559	649	(13.9)
Adjusted PAT	749	390	92.2	484	54.7	1,673	1,690	(1.0)
(Profit)/loss from JV's/Ass/MI	-	-	-	-	-	0	0	-
APAT after MI	749	390	92.2	484	54.7	1,673	1,691	(1.0)
Extra ordinary items	0	0		0		0	0	-
Reported PAT	749	390	92.2	484	54.7	1,673	1,691	(1.0)
Reported EPS	18.6	10.3	81.5	11.6	60.5	41	44	(7.5)
Margins (%)			(bps)		(bps)			(bps)
EBIDTA	27.5	18.8	870	21.9	560	22.8	21.4	130
EBIT	22.8	15.3	750	16.9	590	17.9	18.4	(50)
EBT	25.8	15.2	1,060	19.3	650	20.5	22.0	(140)
PAT	19.9	10.9	900	13.6	640	15.4	15.9	(50)
Effective Tax rate	22.9	28.4	(550)	29.8	(700)	25.0	27.7	(270)

Source: Company, BOBCAPS Research

FIG 2 – DEC'19 QUARTER OPERATING METRICS

Particulars	Q3FY20	Growth ((%)
Farticulars	(% Contr. to Revenue)	ୡୢ୶	Y₀Y
Revenue by Geography (%)			
North America	66.0	1.9	8.6
Europe	28.0	7.2	5.3
ROW	6.0	3.4	(21.0)
Client Contribution to Revenue			
Top 10 (%)	65.1	2.7	(3.2)
Non-Top 10 client revenues	34.9	4.6	10.4
Total Employees	8,785	(4)	(7.6)
Billing Mix			
FTE	69.0	(0.9)	(0.3)
Managed Services Revenues	31.0	14.5	18.5
Onsite Revenues	25.0	3.4	12.2
Offshore Revenues	75.0	3.4	0.5
Currency Concentration			
USD	80.0	2.1	1.2
Euro	12.0	12.8	21.4
GBP	6.0	3.4	(13.3)

Source: Company, BOBCAPS Research.



Valuation methodology

We believe that lower revenue productivity, weaker margins, dimmer growth visibility and an increasing mix of non-annuity business now render ECLX comparable to BPO rather than IT services players. We thus value the stock at a lower P/E multiple of 7.2x (unchanged), a 20% discount to the five-year average 12-month forward P/E of BPO peer Firstsource Solutions (FSOL: Not Rated). Post the Q3 beat, we raise FY21/FY22 EPS by 4%/3% – on rolling valuations forward, we arrive at a revised Mar'21 target price of Rs 490 (vs. Rs 450 earlier).

Over the last three years, ECLX has undergone a structural downward reset to operating margins led by a changing business mix in favour of onsite revenues. Even though margins appear to be bottoming out, growth visibility remains a concern. Cut to SELL from REDUCE.

		FY20E			FY21E			FY22E	
(Rs mn) -	Old	New	Change (%)	Old	New	Change (%)	Old	New	Change (%)
Revenues (US\$ mn)	203.1	203.5	0.2	226.4	223.8	(1.2)	257.9	256.9	(0.4)
YoY growth (%)	1.1	1.4	-	11.5	10.0	-	13.9	14.8	-
Revenues	14,372	14,481	0.8	16,119	15,934	(1.1)	18,066	17,997	(0.4)
EBIT	2,289	2,669	16.6	2,759	2,883	4.5	3,159	3,236	2.4
EBIT margins (%)	15.9	18.4	-	17.1	18.1	-	17.5	18.0	-
Net Profits	1,748	2,080	19.0	2,240	2,337	4.3	2,506	2,573	2.7
EPS (Rs)	46.4	55.3	19.0	59.5	62.1	4.3	66.6	68.3	2.7

FIG 3 - REVISED ESTIMATES

Source: BOBCAPS Research

FIG 4 – RELATIVE STOCK PERFORMANCE



Source: NSE

Key risks

Upside risks to our estimates include:

- a sharper recovery in demand especially for the offshore business,
- stronger-than-expected traction in large accounts, and
- sharp favourable currency movement.



FINANCIALS

Income Statement

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue	13,651	14,305	14,481	15,934	17,997
EBITDA	3,668	3,092	3,365	3,665	4,129
Depreciation	483	447	695	782	894
EBIT	3,185	2,645	2,669	2,883	3,236
Net interest income/(expenses)	0	0	(179)	(152)	(140)
Other income/(expenses)	390	469	360	470	429
Exceptional items	213	0	0	0	0
EBT	3,787	3,114	2,851	3,201	3,524
Income taxes	896	832	771	864	952
Extraordinary items	0	0	0	0	0
Min. int./Inc. from associates	4	0	0	0	0
Reported net profit	2,887	2,283	2,080	2,337	2,573
Adjustments	0	0	0	0	0
Adjusted net profit	2,887	2,283	2,080	2,337	2,573

Balance Sheet

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Accounts payables	0	0	0	0	0
Other current liabilities	1,981	1,960	1,984	2,183	2,465
Provisions	60	78	79	87	99
Debt funds	63	63	63	63	63
Other liabilities	152	152	152	152	152
Equity capital	384	384	384	384	384
Reserves & surplus	11,669	10,120	10,949	11,879	12,904
Shareholders' fund	12,054	10,505	11,333	12,263	13,288
Total liabilities and equities	14,311	12,758	13,612	14,749	16,068
Cash and cash eq.	4,403	2,519	3,559	4,471	5,400
Accounts receivables	2,328	2,352	2,380	2,619	2,958
Inventories	0	0	0	0	0
Other current assets	2,371	2,547	2,579	2,838	3,205
Investments	1,653	1,653	1,653	1,653	1,653
Net fixed assets	1,215	1,346	1,099	828	510
CWIP	1	150	150	150	150
Intangible assets	2,220	2,220	2,220	2,220	2,220
Deferred tax assets, net	121	121	121	121	121
Other assets	0	0	0	0	0
Total assets	14,311	12,758	13,612	14,749	16,068

Source: Company, BOBCAPS Research



Cash Flows

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Net income + Depreciation	4,278	2,729	2,775	3,118	3,466
Interest expenses	(142)	(469)	(181)	(318)	(289)
Non-cash adjustments	0	0	0	0	0
Changes in working capital	(27)	(204)	(35)	(291)	(413)
Other operating cash flows	(1,058)	0	0	0	0
Cash flow from operations	3,050	2,057	2,559	2,510	2,765
Capital expenditures	(415)	(429)	(449)	(510)	(576)
Change in investments	861	0	0	0	0
Other investing cash flows	(183)	469	181	318	289
Cash flow from investing	263	40	(268)	(192)	(287)
Equities issued/Others	87	(2,607)	0	0	0
Debt raised/repaid	53	0	0	0	0
Interest expenses	(3,135)	0	0	0	0
Dividends paid	(40)	(1,374)	(1,252)	(1,406)	(1,548)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(3,035)	(3,981)	(1,252)	(1,406)	(1,548)
Changes in cash and cash eq.	278	(1,884)	1,040	912	930
Closing cash and cash eq.	4,403	2,519	3,559	4,471	5,400

Per Share

Y/E 31 Mar (Rs)	FY18A	FY19A	FY20E	FY21E	FY22E
Reported EPS	74.5	60.1	55.3	62.1	68.3
Adjusted EPS	74.5	60.1	55.3	62.1	68.3
Dividend per share	1.0	1.0	27.6	31.0	34.2
Book value per share	320.2	279.1	301.1	325.8	353.0

Valuations Ratios

Y/E 31 Mar (x)	FY18A	FY19A	FY20E	FY21E	FY22E
EV/Sales	1.5	1.4	1.4	1.3	1.1
EV/EBITDA	5.5	6.3	6.0	5.6	4.8
Adjusted P/E	8.4	10.4	11.3	10.1	9.2
P/BV	2.0	2.2	2.1	1.9	1.8

DuPont Analysis

Y/E 31 Mar (%)	FY18A	FY19A	FY20E	FY21E	FY22E
Tax burden (Net profit/PBT)	76.2	73.3	73.0	73.0	73.0
Interest burden (PBT/EBIT)	118.9	117.7	106.8	111.0	108.9
EBIT margin (EBIT/Revenue)	23.3	18.5	18.4	18.1	18.0
Asset turnover (Revenue/Avg TA)	96.5	105.7	109.8	112.4	116.8
Leverage (Avg TA/Avg Equity)	1.2	1.2	1.2	1.2	1.2
Adjusted ROAE	23.9	20.2	19.0	19.8	20.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets



Ratio Analysis					
Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
YoY growth (%)					
Revenue	2.6	4.8	1.2	10.0	12.9
EBITDA	(21.8)	(15.7)	8.8	8.9	12.7
Adjusted EPS	(15.7)	(19.4)	(8.0)	12.3	10.1
Profitability & Return ratios (%)					
EBITDA margin	26.9	21.6	23.2	23.0	22.9
EBIT margin	23.3	18.5	18.4	18.1	18.0
Adjusted profit margin	21.2	16.0	14.4	14.7	14.3
Adjusted ROAE	23.9	20.2	19.0	19.8	20.1
ROCE	38.2	32.8	32.9	35.9	40.1
Working capital days (days)					
Receivables	60	60	60	57	57
Inventory	0	0	0	0	0
Payables	65	64	65	62	61
Ratios (x)					
Gross asset turnover	11.0	11.2	11.8	16.5	26.9
Current ratio	4.5	3.6	4.1	4.4	4.5
Net interest coverage ratio	NA	NA	NA	NA	NA
Adjusted debt/equity	(0.4)	(0.2)	(0.3)	(0.4)	(0.4)

Source: Company, BOBCAPS Research



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

HISTORICAL RATINGS AND TARGET PRICE: ECLERX SERVICES (ECLX IN)



B - Buy, A - Add, R - Reduce, S - Sell

Rating distribution

As of 31 December 2019, out of 83 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 18 are rated ADD, 9 are rated REDUCE and 6 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH00000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

ECLERX SERVICES



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.